Kite is one of a growing number of drug and biotech companies relying on federal laboratories .Analysts expect the company to Kite least $ 200 , 000 for the new treatment , which is intended as a    therapy for patients .While the law allows the government to demand    concessions from its    partners ,    government has declined the government so with Kite and generally disdains the practice .Insisting on lower prices , federal researchers say , would drive away innovative partners that speed the    process and benefit patients .